Table 1 Clinical characteristics of 21 PDAC patients.

From: Tumor organoids improve mutation detection of pancreatic ductal adenocarcinoma

 

Total patients n = 21

Treatment-naïve patients n = 11

FOLFIRINOX-treated patients n = 10

P-value

Sex

0.659

 Female

7

3

4

 Male

14

8

6

 Age at biopsy (Mean, Year)

70.57

73.6

67.2

0.071

TNM category at resectiona

0.003

 pT2N2

4

4

0

 ypT2N0

3

0

3

 pT2N0

2

2

0

 pT3N1

2

2

0

 ypT2N1

2

0

2

 pT1N0

1

1

0

 pT1N1

1

1

0

 pT2N1

1

1

0

 ypT1N0

1

0

1

 ypT1N1

1

0

1

 ypT2N2

1

0

1

 ypT3N1

1

0

1

 ypT3N2

1

0

1

Tumor differentiation

0.553

 Moderate

10

6

4

 Poor

8

4

4

 Poor-moderate

1

1

0

 **

2

0

2

Resection marginb

0.387

 R0

12

5

7

 R1

9

6

3

Adjuvant therapy

   

0.008

 None

13

4

9

 FOLFIRINOX

5

5

0

 Gemcitabine

2

2

0

 Dendritic cell vaccination

1

0

1

Progression

0.635

 Yes

15

7

8

 No

6

4

2

PFS (Mean, Month)

20.43

20.2

20.7

0.751

OS (Mean, Month)

24.19

25

23.3

0.550

  1. aAccording to AJCC 8th edition staging system. b According to the definition of the UK Royal College of Pathologists. PFS = Progression-free survival, OS = Overall survival. ** No differentiation grade is reported. P-values are calculated using the Wilcoxon rank sum test and Fisher’s exact test.
Back to article page